CTOs on the Move

Axogen Incorporated

www.axogeninc.com

 
Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.axogeninc.com
  • 13631 Progress Boulevard Suite 400
    Alachua, FL USA 32615
  • Phone: 386.462.6800

Executives

Name Title Contact Details

Funding

Axogen Incorporated raised $17.5M on 08/27/2015

Similar Companies

Imago BioSciences

Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.

Operon Biotechnologies

Operon Biotechnologies, Inc is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alumis

We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Lifesprout

Revolutionary Products for Soft Tissue Replacement and Regeneration

Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.